Seres Therapeutics Equity 2024

Seres Therapeutics Aktienanalyse

What does Seres Therapeutics do?

Seres Therapeutics Inc is a company specializing in the development of microbiome therapeutics. The company was founded in 2010 by a group of scientists from Harvard University who recognized the potential of the microbiome and were excited by the fact that it has a multitude of impacts on human health. Seres Therapeutics' headquarters are located in Cambridge, Massachusetts, USA. The business model of Seres Therapeutics is based on the research, development, and commercialization of therapeutics based on the microbiome. The microbiome is the collection of all microorganisms, including bacteria, viruses, and fungi, that live in the human body. Seres Therapeutics firmly believes that the microbiome plays a crucial role in maintaining health and aims to develop innovative therapies that can improve the immune system and strengthen the body's defenses based on this. Seres Therapeutics' products are designed for the treatment of gastrointestinal tract diseases, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. The company's products harness the potential of the microbiome to improve gut health, particularly by restoring the natural balance of gut flora. In 2016, Seres Therapeutics launched its first approved drug on the market - SER-109, a treatment for recurrent Clostridium difficile infections (CDI). CDI is an infectious disease caused by the bacterium Clostridium difficile and is commonly associated with antibiotic therapies. SER-109 has proven effective in reducing the frequency of CDI infections, making it the first approved microbiome-based therapeutic. Seres Therapeutics is also working on the development of other products. The company has conducted several Phase 2 clinical trials demonstrating the efficacy of its preparations for the treatment of inflammatory bowel disease. Other products in Seres Therapeutics' pipeline are currently being tested for their effectiveness in combating cancer and autoimmune diseases, where the microbiome also plays an important role. Seres Therapeutics is also working to expand its business into other markets. The company has entered into partnerships with leading pharmaceutical companies such as Nestlé and AstraZeneca to explore the potential of microbiome therapy in various indications. Another important initiative of Seres Therapeutics is the exploration of the use of artificial intelligence to identify new microbiome-based therapeutics and improve drug development. Overall, Seres Therapeutics Inc has written a fascinating story by recognizing the potential of the microbiome in combating diseases. The company is on track to become a leading provider of microbiome-based therapeutics and continues its efforts to provide innovative solutions to future medical challenges. Seres Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Seres Therapeutics's Equity

Seres Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Seres Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Seres Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Seres Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Seres Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Seres Therapeutics Stock

What is the equity of Seres Therapeutics this year?

Seres Therapeutics has equity of -44.86 M USD this year.

What was the equity of Seres Therapeutics compared to the previous year?

The equity of Seres Therapeutics has increased/decreased by -515.33% decreased compared to the previous year.

What impact does a high equity have on investors of Seres Therapeutics?

A high equity is advantageous for investors of Seres Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Seres Therapeutics?

A low equity can be a risk for investors of Seres Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Seres Therapeutics affect the company?

An increase in equity of Seres Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Seres Therapeutics affect the company?

A reduction in equity of Seres Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Seres Therapeutics?

Some factors that can affect the equity of Seres Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Seres Therapeutics so important for investors?

The equity of Seres Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Seres Therapeutics take to change the equity?

To change equity, Seres Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Seres Therapeutics pay?

Over the past 12 months, Seres Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Seres Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Seres Therapeutics?

The current dividend yield of Seres Therapeutics is .

When does Seres Therapeutics pay dividends?

Seres Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Seres Therapeutics?

Seres Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Seres Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Seres Therapeutics located?

Seres Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Seres Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Seres Therapeutics from 5/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/31/2024.

When did Seres Therapeutics pay the last dividend?

The last dividend was paid out on 5/31/2024.

What was the dividend of Seres Therapeutics in the year 2023?

In the year 2023, Seres Therapeutics distributed 0 USD as dividends.

In which currency does Seres Therapeutics pay out the dividend?

The dividends of Seres Therapeutics are distributed in USD.